Imprimis NJOF recalls eye drops with subpotent drug risk
Imprimis NJOF recalls Prednisolone Sodium Phosphate-Moxifloxacin-Bromfenac eye drops due to subpotent drug levels. This may affect safety and effectiveness of treatment.
Lower-risk recall
Subpotent Drug
Contact the company
What happened, in plain English
Imprimis NJOF has recalled a specific compounded eye drop solution because it contains subpotent drug levels. This means the medication may not work as intended, potentially affecting treatment effectiveness. Read more at govinfonow.com/recall/32741-imprimis-njof-recalls-eye-drops-with-subpotent-drug-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/32741-imprimis-njof-recalls-eye-drops-with-subpotent-drug-risk · Updated September 23, 2026 · FDA enforcement record: FDA #D-0476-2024
Cite this page
“Imprimis NJOF recalls eye drops with subpotent drug risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32741-imprimis-njof-recalls-eye-drops-with-subpotent-drug-risk. Based on FDA recall #D-0476-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0476-2024%22&limit=1).
Why it’s dangerous
The eye drop solution has subpotent drug levels, meaning the active ingredients may be less concentrated than intended. This could lead to the medication not working properly for treating eye conditions.
Who’s affected
People who have received this compounded eye drop solution for eye conditions. Those with eye infections or inflammation may be most at risk if the medication is not effective.
How to tell if you have this one
Check for the product name 'Prednisolone Sodium Phosphate-Moxifloxacin-Bromfenac Sterile Ophthalmic Solution' with the NDC code 71384-340-08. The lot number 23JUN031 and expiration date 07/03/2024 are also key identifiers.
- Brand
Imprimis NJOF- Category
Drug
What to do — step by step
Check Product Details
Look for the NDC code 71384-340-08 and lot number 23JUN031 on the product label.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “U.S. Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 28 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0476-2024 (April 10, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0476-2024 to see it in context.
- Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.